Abstract:BACKGROUND/AIMS: The primary objective of this study was to determine and compare the pharmacokinetic (PK) profiles of inorganic phosphate in the serum after continuous administration of pure glycerophosphate and glycerophosphate contained in total parenteral nutrition (TPN) emulsions. This approach was selected to identify potential PK interactions between TPN components and glycerophosphate.METHODS: The serum PK profile of inorganic phosphate after continuous intravenous administration of a sodium glycerophosphate containing TPN emulsion was determined in 10 healthy, white (5 male/5 female) volunteers. A pure sodium glycerophosphate formulation served as reference. Standard criteria of bioequivalence were applied. Subjects were enrolled in the double-blinded study and were randomly allocated to receive the test and reference preparations on two occasions in a 2-sequence crossover study design. The volunteers received 1/3 of the maximum recommended body weight- (BW) adjusted intravenous daily dosage (13.3 ml/kg BW) of the test drug over a period of 8 h. The amount of total phosphate (0.101 mmol/kg) and duration of administration were identical for the test and reference drugs. Study days were separated by washout periods of at least 88 h. Serum concentrations of total inorganic phosphate were measured serially over a 36-hour period using a validated method. A statistical mixed ANOVA, based on population averages, was used for testing bioequivalence between these study preparations.RESULTS: The 90% confidence intervals (90% CIs) of inorganic phosphate in serum were calculated for the test/reference ratios of the area under the time-concentration curve from time 0 to 36 h (AUC₀₋₃₆), the maximum concentration (C(max)) and the concentration 5 min before the end of infusion (C(ss)) for a bioequivalence range from 0.80 to 1.25. The mean test/reference ratios fell completely within the 90% CIs with values of 1.016 (90% CI 1.005-1.028), 1.013 (90% CI 0.981-1.047) and 0.932 (90% CI 0.886-0.980) for AUC(0-36), C(max) and C(ss), respectively. In total, 3 mild adverse events in the reference group were detected after starting intravenous infusion, while no adverse events were observed in the test group after treatment.CONCLUSION: Primary PK parameters were within the defined bioequivalence range of 0.8-1.25. Thus, inorganic phosphate levels were essentially similar between the two investigational medicinal products tested in the present study. These findings confirm the concept that nutritional components of the test drug do not significantly interact with glycerophosphate. The two study preparations proved to be safe during the investigation.

Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit

[Magnesium in critical care and anesthesiology]

Prospective study of serum and ionized magnesium pharmacokinetics in the treatment of children with severe acute asthma

[Physical compatibility of sodium bicarbonate with other drugs often administered in the intensive care unit]

Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection

Glycerophosphate Does Not Interact with Components of Parenteral Nutrition

Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy

Clinical Pharmacist Participates in the Magnesium Sulfate Therapy and Pharmaceutical Practice in Obstetric Ward

Evaluation of the Stability of Newborn Hospital Parenteral Nutrition Solutions

Electron Microscopy for the Stability Assessment of Parenteral Nutrition Admixtures: Focus on Precipitation

Y-Site Compatibility Studies of Parenteral Nutrition and Other Intravenous Medications in Neonatal and Pediatric Patients: A Review of the Literature Evidence

Glycerophosphate Is Interchangeable with Inorganic Phosphate in Terms of Safety and Serum Pharmacokinetics

Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose

In vivo and in vitro relationship between ionized magnesium and ionized calcium

Compatibility and Stability of Methylprednisolone Sodium Succinate and Granisetron Hydrochloride in 0.9% Sodium Chloride Solution.

Evaluating the effects of intravenous magnesium sulfate for prevention of colistin induced acute kidney injury: an open-label, placebo-controlled, block randomized clinical trial

Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration

Effect of magnesium sulphate infusion on neonatal outcomes in babies with perinatal asphyxia

Ionized Magnesium Correlates With Total Blood Magnesium in Pediatric Patients Following Kidney Transplant

Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma

The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings